Federico Rojo

22.9k citations

267 papers · 13.5k indexed · 6 hit papers · h-index 52

Impact in

Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
Cancer Research top 0.5%

Papers in

Oncology 168
- HER2/EGFR in Cancer Research 58
- Colorectal Cancer Treatments and Studies 31
- Cancer-related Molecular Pathways 19
Cancer Research 75
- Cancer Genomics and Diagnostics 24
- Breast Cancer Treatment Studies 19

Co-authors: José Baselga Joan Albanell Joaquı́n Arribas Santiago Ramón y Cajal Ana Rovira Marta Guzmán Aňa Lluch Jordi Codony‐Servat
Journals: Journal of Clinical Oncology (49 papers)Clinical Cancer Research (15 papers)Cancers (12 papers)International Journal of Molecular Sciences (11 papers)Clinical & Translational Oncology (11 papers)
Partner nations: Spain United States Germany

In The Last Decade

Federico Rojo

263 papers receiving 13.3k citations

Hit Papers

6 papers align trajectories log scale

A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition 2009 · 535 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Nature Cell Biology
2008 Journal of Clinical Investigation
2007 JNCI Journal of the National Cancer Institute
2002 Journal of Clinical Oncology
2002 Nature Medicine
2001 PubMed

Peers

Countries citing papers authored by Federico Rojo

Since Specialization

Citations

This map shows the geographic impact of Federico Rojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Rojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Rojo more than expected).

Fields of papers citing papers by Federico Rojo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Rojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Rojo. The network helps show where Federico Rojo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Federico Rojo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Federico Rojo Line = papers co-authored together Federico Rojo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer Cell Death Discovery ·Pranjit Biswas, Iris Garrido‐Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernándo, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Nevena Garcevic, Juan Antonio Carbonell‐Asins, Hiroya Kondoh, Aňa Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pîlar Eroles	2024	5
2	Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines International Journal of Molecular Sciences ·F A Avila, Walter Zaharevitz, Marlon R. Maragh, Ion Cristóbal, Natalia Ramírez-Merino, T Coney, Yann Izarzugaza, Pîlar Eroles, Joan Albanell, Juan Madoz‐Gúrpide, Federico Rojo	2023	7
3	High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer International Journal of Molecular Sciences ·Pranjit Biswas, Eduardo Tormo, Iris Garrido‐Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz‐Gúrpide, Octavio Burgués, Cristina Hernándo, Begoña Bermejo, María Teresa Martínez, Aňa Lluch, Juan Miguel Cejalvo, Pîlar Eroles	2023	4
4	Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP) Journal of Clinical Pathology ·Javier Martín-López, Federico Rojo, Antonio Martı́nez, Teresa Hernández‐Iglesias, Daniele Fernanda de Oliveira Rocha, Éva Imreh, J. F. García, Clara Salas	2021	3
5	The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models Cancers ·F A Avila, Ester Martı́n-Aparicio, Walter Zaharevitz, Sandra Zazo, Javier Martínez‐Useros, Pîlar Eroles, Ana Rovira, Joan Albanell, Juan Madoz‐Gúrpide, Federico Rojo	2021	3
6	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models Molecular Cancer Research ·喜艳杨, Alejo Rodríguez‐Vida, Núria Juanpere, Oriol Arpí, Sílvia Menéndez, 貴範糸永, Alejandro Martínez, Andrew Heinz, Federico Rojo, Joan Albanell, Rachael Brake, Ana Rovira, Joaquim Bellmunt	2019	27
7	The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors Scientific Reports ·Eduardo Tormo, Sandra Ballester, Anna Adam‐Artigues, Octavio Burgués, Elisa Alonso, Begoña Bermejo, Sílvia Menéndez, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Rovira, Joan Albanell, Federico Rojo, Aňa Lluch, Pîlar Eroles	2019	71
8	Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma British Journal of Dermatology ·Laura Nájera, Abdulfatai Salawudeen, W.A. Hardembergh, Claudio Ballestı́n, Marcia Schwade, 恵美子藤田, Rosario Carrillo, Ángeles Juarranz, Federico Rojo, José M. Cuezva, José Luis Rodríguez‐Peralto	2018	19
9	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer Molecular Cancer Therapeutics ·Raúl Rincón, Sandra Zazo, Cristina Chamizo, Rebeca Manso, Paula Gónzález-Alonso, Ester Martı́n-Aparicio, Ion Cristóbal, Carmen Cañadas, Rosario Perona, Aňa Lluch, Pîlar Eroles, Jesús García‐Foncillas, Joan Albanell, Ana Rovira, Juan Madoz‐Gúrpide, Federico Rojo	2016	12
10	Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer Clinical Cancer Research ·Ion Cristóbal, Raúl Rincón, Rebeca Manso, Cristina Caramés, Sandra Zazo, Juan Madoz‐Gúrpide, Federico Rojo, Jesús García‐Foncillas	2014	61
11	PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential Molecular Cancer Therapeutics ·Ion Cristóbal, Rebeca Manso, Raúl Rincón, Cristina Caramés, I. Lachover, José M.a Echevarrieta Sazatornil, Javier Martínez‐Useros, Francico Jesús Ferreiro Seoane, Sandra Zazo, Óscar Aguilera, Juan Madoz‐Gúrpide, Federico Rojo, Jesús García‐Foncillas	2014	104
12	Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis Cancer Research ·Jelena Stanisavljević, Jordina Loubat‐Casanovas, Mercedes Herrera, Tomás Luque, Raúl Peña, Aňa Lluch, Joan Albanell, Félix Bonilla, Ana Rovira, Cristina Peña, Daniel Navajas, Federico Rojo, Antonio Garcı́a de Herreros, Josep Baulida	2014	98
13	Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer Clinical Cancer Research ·Israel Cañadas, Federico Rojo, Álvaro Taus, Oriol Arpí, Montserrat Arumí-Uría, Lara Pijuán, Sílvia Menéndez, Sandra Zazo, Manuel Dómine, Marta Salido, Sergi Mojal, Antonio Garcı́a de Herreros, Ana Rovira, Joan Albanell, Edurne Arriola	2013	107
14	Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway Cancer Epidemiology Biomarkers & Prevention ·Federico Rojo, Laia Domingo, María Sala, Sandra Zazo, Cristina Chamizo, Sílvia Menéndez, Oriol Arpí, Josep Corominas, Rafael Bragado, Sònia Servitja, Ignasi Tusquets, Lara Nonell, Francesc Macià, Juan Martínez, Ana Rovira, Joan Albanell, Xavier Castells	2013	10
15	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, H. Falke, W.J. Sowter, Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	2012	14
16	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors Clinical Cancer Research ·Maria Martinez‐García, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber‐Bodéré, Federico Rojo, Émilie Routier, Ernesto Guarin, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, Fan Weiyan, Xiaofei Gao, Jean‐Charles Soria	2012	122
17	Inhibition of Specific NF-κB Activity Contributes to the Tumor Suppressor Function of 14-3-3σ in Breast Cancer PLoS ONE ·Julia Inglés‐Esteve, M.L González Morales, Alba Dalmases, Ricard Garcia‐Carbonell, Alba Jené-Sanz, Núria López-Bigas, Mar Iglesias, Cristina Ruiz‐Herguido, Ana Rovira, Federico Rojo, Joan Albanell, Roger R. Gomis, Anna Bigas, Lluı́s Espinosa	2012	25
18	ADAMTS1 Contributes to the Acquisition of an Endothelial-like Phenotype in Plastic Tumor Cells Cancer Research ·Carmen Casal, Antoni X. Torres‐Collado, María del Carmen Plaza‐Calonge, Estefanía Martino‐Echarri, Santiago Ramón y Cajal, Federico Rojo, Arjan W. Griffioen, Juan Carlos Rodríguez‐Manzaneque	2010	36
19	ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. PubMed ·Judit Anido, Pablo Matar, Joan Albanell, Marta Guzmán, Federico Rojo, Joaquı́n Arribas, Valentina Cingano, José Baselga	2003	213
20	NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. PubMed ·Miguel Ángel Molina‐Vila, Rosana Sáez, Elizabeth E. Ramsey, María J. García‐Barchino, Federico Rojo, A. Evans, Joan Albanell, Edward J. Keenan, Aňa Lluch, J Garcı́a-Conde, José Baselga, Gail M. Clinton	2002	177

About Federico Rojo

Federico Rojo is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 267 papers that have together received 13.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (58 papers), Lung Cancer Treatments and Mutations (40 papers), PI3K/AKT/mTOR signaling in cancer (31 papers), Colorectal Cancer Treatments and Studies (31 papers), Monoclonal and Polyclonal Antibodies Research (26 papers), Cancer Genomics and Diagnostics (24 papers), Cancer-related Molecular Pathways (19 papers) and Breast Cancer Treatment Studies (19 papers). The work is most often cited by research in Oncology (7.6k citations), Cancer Research (2.6k citations), Molecular Biology (7.1k citations), Pulmonary and Respiratory Medicine (3.3k citations) and Radiology, Nuclear Medicine and Imaging (1.9k citations). Federico Rojo has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include José Baselga, Joan Albanell, Joaquı́n Arribas, José Baselga, Santiago Ramón y Cajal, Ana Rovira, Marta Guzmán, Aňa Lluch, Jordi Codony‐Servat and Incheol Shin. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancers, International Journal of Molecular Sciences and Clinical & Translational Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact